Cardiomyopathy Market Analysis, Size, Share & Growth Forecast 2026–2034

Mavacamten EXPLORER-HCM 81 Versus 34 Percent LVOT Gradient Reduction to Below 30 mmHg and 37 Percent Peak VO2 Improvement Has Established the First Disease-Specific HCM Treatment Addressing the Sarcomere Hypercontractility Pathophysiology That Beta-Blockers and Disopyramide Do Not Specifically Target.Bristol-Myers Squibb's mavacamten demonstrated 37% absolute improvement in peak oxygen consumption and 82% symptom improvement in EXPLORER-HCM, replacing years of off-label beta-blocker and disopyramide management that addressed symptoms but not the underlying myosin cross-bridge hyperactivity driving LVOT obstruction and diastolic dysfunction. The requirement for CYP2C6 genotyping and echocardiographic LVEF monitoring reflects mavacamten's narrow therapeutic index, requiring specialist cardiology management rather than general practitioner prescribing that is typical for other heart failure and cardiomyopathy drugs. Cytokinetics's aficamten demonstrated non-inferior efficacy in REDWOOD-HCM Phase 2 with a preliminary signal of fewer drug interactions than mavacamten's CYP2C6 metabolism concern, and MAPLE-HCM Phase 3 results will determine whether aficamten can differentiate on tolerability or convenience.

Aficamten SEQUOIA-HCM Second Cardiac Myosin Inhibitor Phase III Success Has Created the First Competitive Therapeutic Class Specifically Designed for the Obstructive HCM Pathophysiology That Previously Had No Approved Disease-Specific Pharmacological Options.Genetic diagnosis of HCM-causing sarcomere gene variants in MYH7, MYBPC3, and TNNT2 enables first-degree family member cascade screening that identifies individuals with genetic HCM before phenotypic expression of hypertrophy, creating a pre-clinical population where preventive approaches may be tested. Invitae and GeneDx HCM gene panels are increasingly incorporated into initial HCM evaluation as the 60-70% genetic positivity rate in referral populations makes genetic diagnosis a routine part of HCM management rather than a specialised research investigation. The genotype-positive phenotype-negative population without echocardiographic hypertrophy but with HCM-causing variants creates a future market for preventive therapy if mavacamten or other cardiac myosin inhibitors can prevent the development of hypertrophy when initiated before wall thickness increases above 15 mm.

LMNA Mutation DCM ICD Primary Prevention Recommendation From the Highest Malignant Arrhythmia Risk Genetic Cardiomyopathy Subtype Has Established the Genotype-Specific ICD Implantation Guideline That Precision Cardiology Applies to Familial DCM Genetic Screening.Titin gene variants are present in approximately 25% of familial and 18% of sporadic DCM, and LMNA mutations define a subset with particularly high risk of sudden cardiac death and malignant ventricular arrhythmias that require early ICD consideration below conventional criteria thresholds. The LMNA cardiomyopathy risk score combining non-sustained VT, ejection fraction, male sex, and specific LMNA variant type stratifies SCD risk and guides ICD timing in a genotype where conventional LVEF-based ICD criteria underestimate arrhythmic risk. Genetic DCM management is creating a specialist cardiomyopathy cardiology subspecialty that integrates genetic counselling, family cascade screening, and genetic variant-specific management algorithms that differ meaningfully from standard DCM management without genetic context.

For related market intelligence, see the Cardiology Drug Market.